Alternative therapy use predicted by higher education, "holistic" health approach -- JAMA.
ALTERNATIVE MEDICINE USE LINKED TO EDUCATION LEVEL, "HOLISTIC" PHILOSOPHY toward health in a survey conducted to examine the factors affecting individuals' decisions to seek various alternative therapies. Users of alternative treatments "tend to be better educated and to hold a philosophical orientation toward health that can be described as holistic," John Astin, PhD, Stanford University, reports in the May 20 issue of the Journal of the American Medical Association. The national survey was mailed in early 1997 to a random sample of 1,500 individuals; 1,035 responses were received.
Learn what's happening at the US FDA. On the go.
More from Archive
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
More from Pink Sheet
Faster EU review of multinational clinical trial applications will deliver limited benefits unless sponsors also speed up site contracting and other start-up activities, a Novartis executive says based on the company’s experience in the FAST-EU pilot.
Singapore has become the 10th country to secure EU recognition of its regulatory framework for active pharmaceutical substances, removing a key documentation requirement for API exports to the bloc.
Varegacestat, Immunome's treatment for adults with desmoid tumors, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.